Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types
Status:
Active, not recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, non-randomised, open-label, multicentric study to investigate the efficacy
and safety of nivolumab monotherapy in 6 cohorts of patients with specific rare cancers who
have unresectable locally advanced or metastatic disease, which is resistant or refractory to
standard therapy, or for which standard therapy does not exist, or is not considered
appropriate, and for which no other experimental treatment options are available.
Phase:
Phase 2
Details
Lead Sponsor:
UNICANCER
Collaborators:
Bristol-Myers Squibb Ligue contre le cancer, France National Cancer Institute, France